Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Ann Oncol. 2019 Dec 1;30(12):2016. doi: 10.1093/annonc/mdz454.
No abstract available

Publication types

  • Published Erratum